Why Is Telix Pharma Stock Soaring Tuesday?

Wedbush analyst David Nierengarten reiterated an Outperform rating on Telix and maintained a $22 price target, signaling continued confidence in the company’s growth trajectory. The reiteration (no change to rating or target) is mildly positive and likely to produce only a modest, stock-specific reaction rather than broader market or sector moves.

Analysis

Wedbush analyst David Nierengarten reiterated an Outperform rating on Telix and maintained a $22 price target, signaling continued confidence in the company’s growth trajectory. The reiteration (no change to rating or target) is mildly positive and likely to produce only a modest, stock-specific reaction rather than broader market or sector moves.